Can Hexo (TSX:HEXO) Stock Double Your Wealth in 2020?

Is it time to consider Hexo stock after an 80% decline since April 2019?

| More on:
edit Jars of marijuana

Image source: Getty Images

Shares of Canada-based marijuana company Hexo (TSX:HEXO)(NYSE:HEXO) are currently trading at $1.98. The stock has lost over 80% since April 2019 and has been one of the worst-performing stocks in the cannabis sector since the start of 2019.

But we know that the optimism surrounding Cannabis 2.0 coupled with the rollout of retail stores in Ontario will hold pot companies in good stead. Further, the decimation witnessed last year has resulted in lower valuations. Hexo is trading at a market cap of $540 million, or 6.6 times forward sales, which might be considered attractive.

What are Hexo’s competitive advantages?

Hexo is one of the top pot companies in Canada. It wants to become a market leader in the adult-use cannabis space with brands such as Hexo, UP, Original Stash, and “powered by Hexo.” The company claims to have the lowest-cost production centres in Canada with a broad distribution network across 10 provinces. Hexo has invested heavily in research to enhance product offerings and customer experiences and has partnerships with global CPG companies.

Hexo is the first to launch a cannabis oil sublingual spray. It is the first licensed producer (LP) in Canada to join the Food & Consumer Products of Canada, which is the country’s largest association representing this industry. Hexo is also the first LP to obtain Kosher certification and partner with a firm in the plant tissue culture space.

Strategic priorities

Hexo has focused on new product offerings as well as leveraging data analytics for decision making to drive top-line growth. As most cannabis companies, including Hexo, are struggling with low profit margins, it is now looking to streamline the supply chain and automate business processes to improve the bottom line.

To achieve its spending targets, Hexo has realigned operating expenses with near-term revenue expectations. Another strategy has been the company’s focus on opening facilities in provinces that have a cost advantage.

Hexo launched a low-cost product known as Original Stash and is priced to compete with Canada’s illegal market, which still accounts for close to 40% of the total market.

Huge market opportunity

Hexo is expected to launch in the United States in 2020. According to Hexo’s presentation, the North American market for cannabis-infused beverages will reach $1.56 billion this year. The global cannabis-infused beverage market is valued at $5.04 billion.

The company has access to 98% of Canada’s population due to its vast distribution network. It has a 33% market share in Quebec, which is the second-largest province in the country. Hexo’s partnership with Molson Coors will help it gain significant traction in the cannabis-infused beverage market.

Molson Coors is a market leader in beverage distribution in Canada, U.S., Mexico, and the United Kingdom. This is a standalone joint venture where costs and profits will be shared on a pro-rata basis.

We can see that Hexo, like so many other players, is banking on future growth and investing heavily in capital expenditures. But the slow rollout of retail stores, competition from the illegal market, and lower-than-expected vaping sales will continue to impact pot stocks in the next few quarters.

The upcoming earnings season will be critical in case marijuana companies are able to reduce inventory levels and drive profit margins higher. Analysts remain cautious for a reason. But is it time to consider pot stocks once again, since the massive decline in valuations over the last year?

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends HEXO. and HEXO. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »